Special Issue "Pathogenic Escherichia coli: Infections and Therapies"
Deadline for manuscript submissions: closed (1 July 2020).
Interests: Adherence-Invasive Escherichia coli pathogenicity; Adherence-Invasive Escherichia coli molecular markers; Escherichia coli pathoadaptive mutations; Escherichia coli resistance to antimicrobials; effective therapies against Adherence-Invasive Escherichia coli; intra-species diversity of gut Escherichia coli; Escherichia coli postbiotics
In addition to being an important member of the normal intestinal microflora of humans and other mammals, the species pathogenic Escherichia coli contains many pathotypes, Enterotoxigenic E. coli (ETEC), Enteroinvasive E. coli (EIEC), Enterohemorrhagic E. coli (EHEC) and so on. That cause a variety of diseases, such as diarrhoea or dysentery, and other pathotypes cause extra-intestinal infections, including urinary tract infections and meningitis. Moreover, Adherent-Invasive E. coli (AIEC), a group of E. coli strains geneticaly close to extraintestinal pathogenic E. coli, have been associated with inflammatory bowel disease.
Virulence factors of pathogenic E. coli can affect a wide range of eukaryotic cellular processes, including cell signalling, ion secretion, protein synthesis, mitosis, cytoskeletal function and mitochondrial function.
Bacterial infections are usually treated with antibiotics. However, the antibiotic sensitivities of different strains of E. coli vary widely. As gram-negative organisms, E. coli are resistant to many antibiotics that are effective against gram-positive organisms. Antibiotics which may be considered to treat E. coli infections include amoxicillin, as well as other semisynthetic penicillins, many cephalosporins, diverse combinations of beta-lactams with beta-lactamase inhibitors, carbapenems, aztreonam, fluoroquinolones, tigecycline, aminoglycosides, trimethoprim-sulfamethoxazole, nitrofurantoin, fosfomycin, colistin... On the other hand, antibiotic treatments have profound effects to the human microbiome, and thus new strategies such as very-narrow-spectrum treatments are welcomed.
Antibiotic Resistance has become a particular problem in recent decades. Researchers have actively been working to develop safe, effective strategy to lower the worldwide incidence of E. coli infection. Such as Phage therapy, Vaccination.
This special issue of "Pathogenic Escherichia coli: Infections and Therapies " aims to publish the more recent advances in the infections and therapies caused by pathogenic E. coli. The issue welcomes various submission types, such as original research papers, short communications, reviews, case reports, and perspectives.
Potential topics for this special issue include, but are not limited to:
- Human or animal, intestinal or extraintestinal infections: therapies, antibiotic resistance, etc.
- High-risk E. coli multiresistant clones: epidemiology and new treatments
- New effective antibiotics against invasive E. coli
- New effective antibiotics against persistent infections by biofilm-forming E. coli
- Phage therapy for E. coli infections
- New very-narrow-spectrum antibiotics for the treatment of E. coli infections
- Interplay between antibiotic resistance and virulence during E. coli infection
- Impact of use of antibiotics in livestock agriculture on the selection of resistant/virulent E. coli clones and spread of them in the environment and transmission to humans.
- Antibiotics to treat dysbiosis?
- Antibiotic treatment in a context of adherent-invasive E. coli (AIEC) overcolonisation
- Old antibiotics still useful to treat E. coli infections
Dr. Martinez-Medina Margarita
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Pathogenic Escherichia
- antibiotic resistance